Cannabis Science, Inc. announced yesterday the negotiations that are in process currently. These negotiations are with several companies in the US and internationally to contract or license its formulations for development, certain rights to manufacturing processes, and the sale in each prospective jurisdiction and or country.
Cannabis Science President & CEO, Dr. Robert Melamede, stated, "We are able to greatly accelerate our company's progress in the New Year by working with others doing research and sales for our cannabinoid medicines by entering into licensing agreements with them. We expect to have definitive agreements signed in the near future."
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
